Vertex Pharmaceuticals
Rating
Updated: Aug 20, 2026Why Price Moved
Vertex Pharmaceuticals stock declined as investors...
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The ...
Latest News
2 days ago · zacks.com
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's WhyVertex Pharmaceuticals (VRTX) concluded the recent trading session at $508.34, signifying a -1.55% move from its prior day's close.
7 days ago · seekingalpha.com
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptVertex Pharmaceuticals Incorporated (VRTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
11 days ago · seekingalpha.com
Vertex Pharmaceuticals Incorporated (VRTX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference TranscriptVertex Pharmaceuticals Incorporated (VRTX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
11 days ago · seekingalpha.com
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Wells Fargo 21st Annual Healthcare Conference TranscriptVertex Pharmaceuticals Incorporated (VRTX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
13 days ago · zacks.com
Vertex Pharmaceuticals (VRTX) Suffers a Larger Drop Than the General Market: Key InsightsIn the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $528.9, indicating a -3.15% shift from the previous trading day.
13 days ago · zacks.com
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to KnowVertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
19 days ago · zacks.com
Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report?Vertex (VRTX) reported earnings 30 days ago. What's next for the stock?
1 month ago · defenseworld.net
AssuredPartners Investment Advisors LLC Invests $2.06 Million in Vertex Pharmaceuticals Incorporated $VRTXAssuredPartners Investment Advisors LLC purchased a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 4,147 shares of the pharmaceutical company's stock, valued at approximately $2,060,000. Several other institutional investors
2 months ago · zacks.com
VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View RaisedVertex's Q2 earnings miss estimates, but revenues beat. It lifts its 2026 sales outlook, and sees growing contributions from newer products.
2 months ago · zacks.com
VRTX Q2 Earnings Call Highlights Launch Momentum & Higher OutlookVertex raises its 2026 revenue outlook as CF growth, newer products and a near-term renal launch strengthen its diversification push.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove VRTX